Emotra AB (“Emotra”) is pleased to announce that we have reached an agreement with an Italian research group concerning so-called “research rental”. 181127 - Emotra -Newsletter - Agreement with Italian research group
As Emotra announced in a press release on November 16, a letter of intent has been signed with a London-based psychiatric hospital. The agreement will allow the hospital to evaluate EDOR® in clinical practice for a limited period of time. 181123- Emotra - Newsletter - English hospital gets started
Emotra is proud to announce that Lars-Håkan Thorell, Emotra’s Head of Research and the inventor of EDOR®, in his research for Emotra has demonstrated the biological mechanism behind hyporeactivity. This discovery explains why an increased suicide risk can be identified by EDOR®. 181120- Emotra - PM - Important discoveries in research
Emotra hereby announces that the company has signed a letter of intent with a large, London-based psychiatric hospital. This deal grants the hospital the right to use EDOR® during a limited trial period. The agreement includes 30 tests free of charge, after which Emotra will be compensated for each test analysis. 181116- Emotra - [...]
Emotra has recently held a number of meetings with decision-makers who intend to move forward with testing of EDOR® in their regular clinical practice. The psychiatric caregivers that Emotra has met this autumn have grown increasingly aware of how EDOR test results can supplement the diagnoses they make in their clinical examinations. 181114- Emotra [...]
Today, November 1, 2018, EMOTRA AB (“Emotra”) announced that its Board of Directors have decided on a new rights issue of shares. This rights issue will comprise a maximum of 23,978,953 shares and the public has also been invited to participate. 181101 - Emotra- PM - Issue resolution
The Board of Directors and the CEO of Emotra AB (publ) hereby present the interim report for the first nine months of 2018. 181024 Interim report Jan-Sept 2018
Emotra’s CEO announces that he is stepping down. Emotra’s board of directors has appointed Marketing Manager Daniel Poté as the new CEO. Daniel will assume this new position immediately. Margit Ferm has stated that she wishes to step down as chairperson of the board, but will continue her engagement as a board member. Claes Holmberg [...]
Yesterday, on October 17, 2018, Emotra hosted a training seminar for doctors and test leaders at a number of clinics that belong to a German psychiatric and psychotherapeutic hospital. This training is the start of a controlled introduction of the test in their clinical practice. The hospital will borrow hardware from us during a defined [...]
Emotra has reached an important stage in its development. A few days ago, a scientific article was published based on a compilation of the results of earlier blind studies. It shows that hyporeactivity is a clear and strong marker for suicide risk. Furthermore, the Company was recently invited by one of Great Britain’s leading chains [...]